See more : Alpha Teknova, Inc. (TKNO) Income Statement Analysis – Financial Results
Complete financial analysis of Deinove SA (ALDEI.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Deinove SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Belite Bio, Inc (BLTE) Income Statement Analysis – Financial Results
- The SPAR Group Ltd (SGPPF) Income Statement Analysis – Financial Results
- UBE Corporation (4208.T) Income Statement Analysis – Financial Results
- Jericho Energy Ventures Inc. (JROOF) Income Statement Analysis – Financial Results
- Venture Corporation Limited (VEMLF) Income Statement Analysis – Financial Results
Deinove SA (ALDEI.PA)
About Deinove SA
DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Oléoactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 367.00K | 323.00K | 163.00K | 39.00K | 73.00K | 793.00K | 492.00K | 155.00K | 51.00K | 668.00K | 637.00K | 603.00K | 4.00K |
| Cost of Revenue | 3.69M | 3.92M | 7.17M | 4.88M | 4.54M | 4.12M | 4.37M | 3.53M | 2.76M | 2.29M | 2.69M | 1.98M | 1.16M |
| Gross Profit | -3.32M | -3.59M | -7.01M | -4.84M | -4.47M | -3.32M | -3.88M | -3.38M | -2.71M | -1.62M | -2.05M | -1.38M | -1.15M |
| Gross Profit Ratio | -904.09% | -1,112.69% | -4,300.00% | -12,417.95% | -6,117.81% | -419.04% | -788.21% | -2,178.71% | -5,309.80% | -242.96% | -322.45% | -228.36% | -28,850.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 0.00 | 0.00 |
| Other Expenses | 4.52M | 4.53M | 5.19M | 5.62M | 5.21M | 0.00 | 0.00 | -735.00K | 21.00K | 543.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.52M | 4.53M | 5.19M | 5.62M | 5.21M | 4.37M | 4.09M | 3.68M | 2.81M | 2.23M | 1.94M | 1.16M | 725.00K |
| Cost & Expenses | 8.21M | 8.45M | 12.37M | 10.51M | 9.75M | 8.49M | 8.46M | 7.22M | 5.57M | 4.52M | 4.63M | 3.14M | 1.88M |
| Interest Income | 6.00K | 12.00K | 0.00 | 0.00 | 0.00 | 86.00K | 67.00K | 83.00K | 137.00K | 425.00K | 311.00K | 81.00K | 11.00K |
| Interest Expense | 50.00K | 19.00K | 9.00K | 22.00K | 13.00K | 70.00K | 81.00K | 120.00K | 15.00K | 1.00K | 267.00K | 60.00K | 0.00 |
| Depreciation & Amortization | 440.00K | 1.42M | 1.74M | 1.57M | 1.55M | 709.00K | 656.00K | 545.00K | 367.00K | 166.00K | 416.00K | 175.00K | 33.00K |
| EBITDA | -6.89M | -6.70M | -10.47M | -8.90M | -8.13M | -6.87M | -7.24M | -6.43M | -5.02M | -3.09M | -3.26M | -2.28M | -1.85M |
| EBITDA Ratio | -1,877.66% | -2,075.23% | -6,420.25% | -22,807.69% | -11,139.73% | -866.46% | -1,471.95% | -4,149.68% | -9,841.18% | -461.98% | -512.24% | -377.94% | -46,150.00% |
| Operating Income | -7.33M | -8.13M | -12.20M | -10.47M | -9.68M | -7.69M | -7.97M | -7.06M | -5.52M | -3.85M | -3.99M | -2.54M | -1.88M |
| Operating Income Ratio | -1,997.55% | -2,515.48% | -7,485.28% | -26,838.46% | -13,261.64% | -969.99% | -1,618.90% | -4,554.84% | -10,829.41% | -576.35% | -626.53% | -420.40% | -47,000.00% |
| Total Other Income/Expenses | -561.00K | -21.00K | -33.00K | -6.00K | -5.00K | 298.00K | -24.00K | -772.00K | 143.00K | 967.00K | 45.00K | 8.00K | 10.00K |
| Income Before Tax | -7.89M | -8.15M | -12.23M | -10.47M | -9.69M | -7.39M | -7.99M | -7.83M | -5.38M | -2.88M | -3.95M | -2.53M | -1.87M |
| Income Before Tax Ratio | -2,150.41% | -2,521.98% | -7,505.52% | -26,853.85% | -13,268.49% | -932.41% | -1,623.78% | -5,052.90% | -10,549.02% | -431.59% | -619.47% | -419.07% | -46,750.00% |
| Income Tax Expense | -901.00K | -1.35M | -2.43M | -2.01M | -2.43M | -1.12M | -1.63M | -1.37M | -1.96M | -903.00K | -682.00K | -276.00K | -621.00K |
| Net Income | -6.99M | -6.79M | -9.80M | -8.46M | -7.26M | -6.28M | -6.36M | -6.46M | -3.42M | -1.98M | -3.28M | -2.25M | -1.25M |
| Net Income Ratio | -1,904.90% | -2,102.79% | -6,012.88% | -21,689.74% | -9,939.73% | -791.80% | -1,291.87% | -4,166.45% | -6,705.88% | -296.26% | -514.44% | -373.30% | -31,225.00% |
| EPS | -0.24 | -0.28 | -0.59 | -0.61 | -0.68 | -0.70 | -0.74 | -1.18 | -0.68 | -0.40 | -0.67 | -0.46 | -0.29 |
| EPS Diluted | -0.24 | -0.28 | -0.59 | -0.61 | -0.68 | -0.70 | -0.74 | -1.18 | -0.68 | -0.40 | -0.67 | -0.46 | -0.29 |
| Weighted Avg Shares Out | 28.60M | 24.52M | 16.60M | 13.86M | 10.72M | 8.97M | 8.59M | 5.47M | 5.06M | 4.94M | 4.89M | 4.89M | 4.24M |
| Weighted Avg Shares Out (Dil) | 28.60M | 24.52M | 16.60M | 13.86M | 10.72M | 8.97M | 8.59M | 5.47M | 5.06M | 4.94M | 4.89M | 4.89M | 4.24M |
Source: https://incomestatements.info
Category: Stock Reports